Aloeplant en chemo: Aloe extract van de Aloe plant naast chemo geeft significant meer 3-jaars overlevingen bij patienten met uitgezaaide kanker, significant meer complete remissies en significant betere controle van de ziekte dan alleen chemo. Aldus gerandomiseerde studie bij 240 patienten met longkanker, darmkanker, alvleesklierkanker en maagkanker. Artikel update 4 april 2011

 22 juni 2009: Bron: 1: In Vivo. 2009 Jan-Feb;23(1):171-5

Een abstract gemaakt van de Aloe Vera plant geeft aanvullend op verschillende vormen van chemo therapie bij verschillende vormen van uitgezaaide kanker een signicant beter effect op de 3-jaars overleving en op de controle over de ziekte. Dit blijkt uit een gerandomiseerde studie met 240 kankerpatienten. Het volledige studierapport is hier digitaal te bekijken of downloaden.

Er deden patienten aan deze studie mee met vergevorderde niet-klein-cellige longkanker, darmkanker, alvleesklierkanker en maagkanker Opvallend dat er 12 complete remissies waren in de Aloe groep van 119 patienten tegenover slechts 4 complete remissies met alleen chemo onder 122 patienten. De controle van de ziekte (stabiele ziekte) bleek bewerkstelligd bij 80 van de 119 in de Aloe plus chemo groep en bij 60 van de 121 bij de chemogroep. Een significantg verschil.

By considering the overall tumor histotypes, the percentages of complete responses (CR) and partial responses (PR) achieved in patients concomitantly treated with aloe were significantly higher than in those who received chemotherapy alone (40/119 (34%) vs. 23/121 (19%), p<0.01). A CR occurred in 12/119 (10%) patients concomitantly treated with aloe and in only 4/121 (3%) patients treated with chemotherapy alone. This difference was statistically significant (p<0.01). Stable disease (SD) was achieved in 37/121 (31%) patients treated with chemotherapy alone and in 40/119 (34%) patients who received a concomitant aloe administration. The disease control (DC=CR+PR+SD) obtained in patients concomitantly treated with aloe showed a significantly higher percentage than that found in patients who received chemotherapy alone (80/119 (67%) vs. 60/121 (50%), p<0.0l).

A randomized study of chemotherapy versus biochemotherapy with chemotherapy plus Aloe arborescens in patients with metastatic cancer.
Lissoni P, Rovelli F, Brivio F, Zago R, Colciago M, Messina G, Mora A, Porro G.
Division of Radiation Oncology, St. Gerardo Hospital, Monza, Milan, Italy. p.lissoni@hsgerardo.org
 
BACKGROUND: The recent advances in the analysis of tumor immunobiology suggest the possibility of biologically manipulating the efficacy and toxicity of cancer chemotherapy by endogenous or exogenous immunomodulating substances. Aloe is one of the of the most important plants exhibiting anticancer activity and its antineoplastic property is due to at least three different mechanisms, based on antiproliferative, immunostimulatory and antioxidant effects. The antiproliferative action is determined by anthracenic and antraquinonic molecules, while the immunostimulating activity is mainly due to acemannan.
 
PATIENTS AND METHODS: A study was planned to include 240 patients with metastatic solid tumor who were randomized to receive chemotherapy with or without Aloe. According to tumor histotype and clinical status, lung cancer patients were treated with cisplatin and etoposide or weekly vinorelbine, colorectal cancer patients received oxaliplatin plus 5-fluorouracil (5-FU), gastric cancer patients were treated with weekly 5-FU and pancreatic cancer patients received weekly gemcitabine. Aloe was given orally at 10 ml thrice/daily.
 
RESULTS: The percentage of both objective tumor regressions and disease control was significantly higher in patients concomitantly treated with Aloe than with chemotherapy alone, as well as the percent of 3-year survival patients.
 
CONCLUSION: This study seems to suggest that Aloe may be successfully associated with chemotherapy to increase its efficacy in terms of both tumor regression rate and survival time.